News of Note—MaxiVAX, PATH and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week.

> International nonprofit organization PATH updated its brand and website. Release

> Swiss biotech MaxiVAX received an FDA Investigational New Drug Application for MVX-ONCO-1 and appointed T. Scott Johnson, M.D., a founder of The Medicines Company, as its chairman. Release (PDF) | Release (PDF)

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Pfenex received a milestone payment from Merck after the pharma giant started a phase 3 trial of its 15-valent pneumococcal vaccine. The candidate is subject to a 2007 agreement between the companies that allowed Merck to utilize the biotech's technology platform. Release

> Agenus named Sunil Gupta, M.D., as VP of regulatory and pharmacovigilance and Anna Wijatyk, M.D., as VP of clinical development. Release

Read more on

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.